Protein Kinase Inhibitors: all 15,278 studies that test it

Page 115 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPCStatus unknownNCT02525068Phase 2
• Sirolimus for the Treatment of HyperinsulinismWithdrawnNCT02524639Phase 1/2
• Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2
• An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT02522910Phase 1/2
• Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143CompletedNCT02521389Phase 1
• Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1
• A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02520752Phase 1
• Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02518802Phase 3
• Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT02518555Phase 2
• The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT02515435Phase 2
• A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced CancersCompletedNCT02514603Phase 1
• Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of AfatinibStatus unknownNCT02511847Phase 2
• AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
• Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsCompletedNCT02511639Phase 3
• A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknownNCT02511340Phase 2
• Safety and PK Study of CC-90001 in Subjects With Pulmonary FibrosisCompletedNCT02510937Phase 1
• Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer CellsStatus unknownNCT02510469Phase 2/3
• Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric CancerStatus unknownNCT02509806Phase 2/3
• suPERficial Slow-flow Vascular malFORMations Treated With sirolimUSCompletedNCT02509468Phase 2
• A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Phase 1
• Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and PainCompletedNCT02508337Phase 3
• WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and NeckCompletedNCT02508246Phase 1
• Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast CancerCompletedNCT02506556Phase 2
• A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER GeneCompletedNCT02506517Phase 2
• Minimal Islet Transplant at Diabetes OnsetCompletedNCT02505893Phase 2
• Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular CarcinomaStatus unknownNCT02504983Phase 4
• AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesStatus unknownNCT02504346Phase 2
• Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02503722Phase 1
• Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02503709Phase 1
• Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerCompletedNCT02503358Phase 1
• A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownNCT02503033Phase 1
• Afatinib, Paclitaxel, 2nd Line, Advanced Gastric CancerCompletedNCT02501603Phase 2
• Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line TherapyStatus unknownNCT02501551Phase 2
• A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR MutationsTerminatedNCT02500927Phase 2
• Phase I Study of Pyrotinib in Patients With HER2-positive Solid TumorsStatus unknownNCT02500199Phase 1
• Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)Status unknownNCT02499614Phase 2
• Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1
• A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)CompletedNCT02495519Phase 2
• Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or OlderActive, not recruitingNCT02494882Phase 1
• TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
• Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot StudyStatus unknownNCT02493465Phase 4
• Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer PatientsCompletedNCT02490488Phase 2/3
• Donafenib Monotherapy for Previously Treated Metastatic Colorectal CancerCompletedNCT02489916Phase 1/2
• Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell CarcinomaCompletedNCT02489695Phase 2
• Donafenib Monotherapy for Previously Treated Metastatic Gastric CancerTerminatedNCT02489214Phase 1/2
• A Study of Donafenib Monotherapy in Advanced Oesophageal CancerTerminatedNCT02489201Phase 1/2
• Maintaining ERBB Blockade in EGFR-mutated Lung CancerTerminatedNCT02488694Phase 2
• A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibWithdrawnNCT02487316Phase 4
• Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyCompletedNCT02486354Phase 3
• Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy SubjectsCompletedNCT02485769Phase 1
• Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the LungTerminatedNCT02485652Phase 2
• Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseStatus unknownNCT02484755Phase 2
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2
• Study of Oral PQR309 in Patients With Advanced Solid TumorsCompletedNCT02483858Phase 1
• Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursCompletedNCT02482311Phase 1
• Rapamycine vs Placebo for the Treatment of Inclusion Body MyositisCompletedNCT02481453Phase 2/3
• PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKITerminatedNCT02479490Phase 2
• Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid TumorsCompletedNCT02478866Phase 1
• Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedNCT02476955Phase 1
• Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast CancerCompletedNCT02476539Phase 1
• Study of Topical Ocular PAN-90806 in PDRCompletedNCT02475109Phase 1
• INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic FunctionCompletedNCT02474537Phase 1
• Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
• The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic DisordersTerminatedNCT02472509Phase 4
• PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate CancerCompletedNCT02472275Phase 1
• Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.SuspendedNCT02470065Phase 2
• Ruxolitinib in Combination With AutotransplantWithdrawnNCT02469974Not applicable
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationTerminatedNCT02468661Phase 1
• A Study to Assess the Relative Bioavailability of JNJ-42756493 TabletsCompletedNCT02466815Phase 1
• Study of Regorafenib and Sildenafil for Advanced Solid TumorsCompletedNCT02466802Phase 1
• Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal CancerCompletedNCT02465502Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
• Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib TherapyStatus unknownNCT02461849Phase 2
• Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Phase 2/3
• A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
• Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) StudyCompletedNCT02457351Phase 1
• Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid TumorsCompletedNCT02456883Phase 1
• INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
• Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT02455297Phase 2
• Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) PatientsTerminatedNCT02454842Phase 2
• Phase 1 Study of CM082 in Patients With wAMDSuspendedNCT02452385Phase 1
• Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)Status unknownNCT02452294Phase 2
• Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line ChemotherapyCompletedNCT02451956Phase 2
• Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung CancerWithdrawnNCT02451865Phase 1
• Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary CancerCompletedNCT02451553Phase 1
• Rituximab With or Without Ibrutinib for Patients With Advanced Follicular LymphomaTerminatedNCT02451111Phase 2
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
• Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid TumorsCompletedNCT02450149Not applicable
• Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid TumorsCompletedNCT02450136Not applicable
• Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid TumorsCompletedNCT02450123Not applicable
• Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or SkinTerminatedNCT02449681Phase 2
• Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line ChemotherapyTerminatedNCT02449655Phase 2
• The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid TumorsCompletedNCT02449564Not applicable
• Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line TreatmentCompletedNCT02449551Phase 2
• Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid TumorsCompletedNCT02449538Phase 2
• Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)Status unknownNCT02449343Phase 2/3
• Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
• An Investigation of TAS-119 MonotherapyTerminatedNCT02448589Phase 1
• Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2

← Protein Kinase Inhibitors overview